BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37202742)

  • 1. LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
    Chen Y; Ma F; Zhang Z; Guo Y; Shen H; Chen H
    BMC Cancer; 2023 May; 23(1):455. PubMed ID: 37202742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of long noncoding RNA PVT1 attenuates paclitaxel resistance in glioma cells.
    Song T; Yan L; Cai K; Zhao T; Xu M
    Cancer Biomark; 2018; 23(3):447-453. PubMed ID: 30347597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
    Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA-XIST interacts with
    Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
    Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of lncRNA PVT1 Inhibits Glioma Progression by Regulating miR-424 Expression.
    Han Y; Li X; He F; Yan J; Ma C; Zheng X; Zhang J; Zhang D; Meng C; Zhang Z; Ji X
    Oncol Res; 2019 Jun; 27(6):681-690. PubMed ID: 30832754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK/STAT pathway.
    Wang P; Peng X; Zhang J; Wang Z; Meng J; Cen B; Ji A; He S
    Apoptosis; 2018 Dec; 23(11-12):651-666. PubMed ID: 30232656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
    Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
    Wang W; Han S; Gao W; Feng Y; Li K; Wu D
    Cell Mol Neurobiol; 2022 Apr; 42(3):695-708. PubMed ID: 32897512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
    Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
    Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
    Liao Y; Shen L; Zhao H; Liu Q; Fu J; Guo Y; Peng R; Cheng L
    J Cell Biochem; 2017 Jul; 118(7):1889-1899. PubMed ID: 28121023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
    Chen WL; Chen HJ; Hou GQ; Zhang XH; Ge JW
    Aging (Albany NY); 2019 Aug; 11(16):6053-6068. PubMed ID: 31469661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
    Fu J; Peng J; Tu G
    Gen Physiol Biophys; 2022 Jul; 41(4):349-355. PubMed ID: 35938968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA BRCAT54 inhibits the tumorigenesis of non-small cell lung cancer by binding to RPS9 to transcriptionally regulate JAK-STAT and calcium pathway genes.
    Yang W; Qian Y; Gao K; Zheng W; Wu G; He Q; Chen Q; Song Y; Wang L; Wang Y; Gu P; Chen B; Zhai R
    Carcinogenesis; 2021 Feb; 42(1):80-92. PubMed ID: 32459848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
    Zhou J; Xu N; Liu B; Wang C; He Z; Lenahan C; Tang W; Zeng H; Guo H
    Cancer Sci; 2022 Aug; 113(8):2681-2692. PubMed ID: 35637600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
    Sun ZY; Jian YK; Zhu HY; Li B
    Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
    Li S; Xie X; Peng F; Du J; Peng C
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.